肺癌中的Oligo复发;在晚期疾病中最可治愈的状态?
1Department of Thoracic Surgery, Tokyo Medical University, Tokyo 160-0023, Japan.
Cancers
|December 17, 2024
概括
晚期非小细胞肺癌 (NSCLC) 中的奥利戈复发可能可以通过联合治疗来治愈. 需要进一步的研究来定义和优化这种潜在可治愈的晚期肺癌状态的治疗方法.
科学领域:
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
- 癌症研究 癌症研究
背景情况:
- 晚期非小细胞肺癌 (NSCLC) 经常复发或进展,尽管有系统治疗.
- 奥利戈复发,定义为有限的转移与控制的原发性病变,代表一个潜在的可治愈状态在先进的NSCLC.
- 目前对原复发的定义是可变的,正在进行讨论.
研究的目的:
- 为了提供一个全面的概述证据支持肺癌中原复发的证据.
- 突出高级NSCLC中形复发的潜在治愈能力.
- 强调需要进一步的研究和精细的治疗策略.
主要方法:
- 审查现有文献和关于NSCLC中原复发的回顾性研究.
- 讨论与oligo-recurrence相关的定义,流行率和结果.
- 考虑结合全身疗法和局部废除疗法 (LATs) 的多式疗法.
主要成果:
- 奥利戈复发并不罕见,在NSCLC病例中发生18-53%.
- 患有形复发的患者表现出相对更好的生存结果.
- 有证据表明,使用LAT的多式联络方法可能为形复发提供治愈潜力.
结论:
- 在NSCLC中Oligo复发是晚期疾病中预后有利的亚组.
- 严格的研究是完善治疗形复发的治疗策略的必要条件.
- 结合系统和局部疗法的定制方法对于优化结果至关重要.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328


